Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tokyo based Kureha Launches Chronic Kidney Drug In Taiwan

This article was originally published in PharmAsia News

Executive Summary

Kureha launched chronic kidney disease therapy Kremezin in Taiwan after obtaining an approval for the drug. Currently patients have to pay out of pocket as Taiwan requires clinic trail data from two countries in order for a drug to be covered by insurance. The company is waiting for results of Phase III clinic trials jointly conducted with Mitsubushi Tanabe in Europe and the U.S. (Click here for more - Japanese language) "Kureha Launches Chronic Kidney Drug In Taiwan And Further Expand Asian Market" - Nikkan Kogyo News (8/12/08)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts